Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Duke University

Summary

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Age ≥ 18 years of age * Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment * Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s) * Patient must sign study-specific informed consent Exclusion Criteria: • None

Locations (5)

Duke Cancer Institute Cary
Cary, North Carolina
RadOnc-Clinical_Trials@dm.duke.edu 919-668-3726
Durham Veterans Administration Health Care System (DVAHCS)
Durham, North Carolina
josephine.gaston@va.gov
Duke University Medical Center
Durham, North Carolina
RadOnc-Clinical_Trials@dm.duke.edu 919-668-3726
Duke Women's Cancer Care Raleigh
Raleigh, North Carolina
RadOnc-Clinical_Trials@dm.duke.edu 919-668-3726
Duke Raleigh Hospital
Raleigh, North Carolina
RadOnc-Clinical_Trials@dm.duke.edu 919-668-3726